RELAÇÃO ENTRE O USO DE INIBIDORES DE BOMBA DE PRÓTONS E O DESENVOLVIMENTO DE DEMÊNCIA SENIL: UMA REVISÃO DE LITERATURA

Cristina Ribeiro Dias Barroso, Ticiani Rios Guedes, Leonardo Silveira Gomes, Vinícius Abrantes Silvestre, Sérgio Elias Vieira Cury

Resumo


Os inibidores da bomba de prótons são uma das classes de medicamentos mais prescritas no mundo, sendo utilizados para tratar os distúrbios relacionados ao aumento da acidez do trato gastrointestinal superior ao inibir a secreção gástrica. No entanto, em vista de recentes estudos que sugerem que o uso crônico de tais medicamentos possuam relação com o aumento do risco para o desenvolvimento de demência senil, torna-se de extrema importância a sua divulgação, principalmente à comunidade médica e científica.

Palavras-chave


Omeprazol. Doença de Alzheimer. Demência.

Texto completo:

PDF

Referências


ALAI, M.; LIN, W.J. Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations. Int J Nanomedicine. v. 18, n. 10, p. 4029-41, 2015.

ALAI, M.; LIN, W.J. Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation. AAPS J. v. 16, n. 3, p. 361-72, 2014.

BADIOLA, N.; ALCALDE, V.; PUJOL, A. et al. The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production. PLOS ONE, v. 8, p. 1-8, 2013.

FALLAHZADEH, M. K.; BORHANI HAGHIGHI, A.; NAMAZI, M. R. Proton pump inhibitors: predisposers to Alzheimer disease?. Journal of clinical pharmacy and therapeutics, v. 35, n. 2, p. 125-126, 2015.

FANG, Y.; WANG, G.; ZHANG, R. et al. Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability. AAPS PharmSciTech.v. 15 n. 3, p. 513-21, 2014.

FAWAZ, M.V.; BROOKS, A.F.; RODNICK, M.E. et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.. ACS Chem Neurosci., v. 5, n. 8, p. 718-30, 2014.

FORGACS, I.; LOGANAYAGAM, A. Overprescribing proton pump inhibitors. BMJ: British Medical Journal, v. 336, n. 7634, p. 2, 2008.

GOMM, W.; VON HOLT, K.; THOMÉ, F. et al. Association of Proton Pump Inhibitors With Risk of Dementia - A Pharmacoepidemiological Claims Data Analysis, JAMA Neurol., v .10, n. 1001, p. 1-7, 2016.

GOYAL, R.K. Distúrbios do Sistema Gastrintestinal: Doenças do esôfago. In: KASPER, D.L.; FAUCI, A.S.; LONGO, D.L., et al. Harrison: Medicina Interna. 16ª Ed. Rio de Janeiro: Mc Graw Hill, 2012.

HAENISCH, B.; VANS HOLT, K.; WIESE, B. et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci, 2015.

INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA – IBGE. Disponível em: . Acesso em: 15 dez 2016.

KUIPERS, E.J. Proton pump inhibitors and gastric neoplasia. Gut., v. 55, p. 1217-21, 2006.

KULLER, L.H. Do proton pump Inhibitors Increase the risk of dementia?. JAMA neurology, v. 73, n. 4, p. 379-381, 2016.

LAM, J.R. et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama, v. 310, n. 22, p. 2435-42, 2013.

LEWIS, H.K. Do Proton Pump Inhibitors Increase the Risk of Dementia? JAMA Neurol. Published online, 2016.

MACKAY, J.D.; BLADON, P.T. Hypomagnesemia due to proton-pump inhibitor therapy: a clinical case series. Q J Med., v. 103, p. 387-95, 2014.

MAXIMOV, G.; KAMNASARAN, D. The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report., DBMC Res Notes, v. 16, n. 6, p. 327, 2013.

MCCOLL, K.E.L.; KENNERLEY, P. Proton pump inhibitors- differences emerge in hepatic metabolism. Digest Wjer Dis., v. 34, p. 461-7, 2012.

MOHER, D.; LIBERATI, A.; TETZLAFF, J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2014.

MOWAT, C.; WILLIAMS, C.; GILLEN, D. et al. Omeprazole, Helicobacter pylori status and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology, v. 119, n. 339-47, 2012.

NISHIDA, T.; TSUJII, M.; TANIMURA, H. et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol. v. 20, n. 15, p. 4362-9, 2014.

NITRINI, R.; CARAMELLI, P.; BOTTINO, C.M.C. et al. Diagnóstico de doença de Alzheimer no Brasil. Arq Neuropsiquiatr., v. 63, n. 3A, p. 720-7, 2013.

NOVOTNA, A.; SROVNALOVA, A.; SVECAROVA, M. et al Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon receptor in human hepatocytes and cell lines. PLoS One. v. 9, n. 6, 2014.

PARK, C.H.; KIM, E.H.; ROH, Y.H. et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis., Journal Pone, v. 9, n. 11, 2014.

POITRAS, P.; GINGRAS, M.H.; REHFELD, J.F. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol, v. 10, p. 199-202, 2012.

PRINCE, M. Bryce, R.; Albanese, E. et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's & Dementia, v. 9, n. 1, p. 63-75, 2013.

ROUCH, L.; CESTAC, P.; HANON, O. et. al. Antihypertensive Drugs, Prevention of Cognitive Decline and Dementia: A Systematic Review of Observational Studies, Randomized Controlled Trials and Meta-Analyses, with Discussion of Potential Mechanisms, CNS Drugs, v. 29, n. 2, p. 40-52, 2015.

SAHARA, S.; SUGIMOTO, M.; UOTANI, T. et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther., v. 38, n. 9, p. 1129-37, 2013.

SHARMA, V.R.; BRANNON, M.A.; CARLOSS, E.A. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. Southern medical journal, v. 97, n. 9, p. 887-889, 2014.

SODHI, R.K.; SINGH, N. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PloS one, v. 8, n. 7, 2013.

SOHAILY, S.A.; DUGGAN, A. Long term management of patients taking proton pump inhibitors. Australian Prescriber, Newcastle, n. 31, p. 5-7, 2013.

STEDMAN, C.A.M.; BARCLAY, M.L. Comparison of the pharmacokinetics, acid suppression and eficacy of proton pump inhibitors. Aliment Pharmacol Ther., v.14, p. 963-78, 2013.

TAMELINI, M.G.; FORLENZA, O.V. Diagnóstico diferencial das demências. Rev. Psiq. Clín., v. 32, n. 3, p. 11930, 2013.

THOMSON, A.B.; SAUVE, M.D.; KASSAM, N. et al. Safety of the long-term use of proton pump inhibitors. World Journal of Gastroenterology, v. 16, n. 19, p. 2323-30, 2013.

TOLMAN, K.G.; SANDERS, S.W.; BUCHI, K.N. et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. Journal of Clinical Gastroenterology, v. 24, n. 2, p. 65-70, 2012.

US FOOD AND DRUG ADMINISTRATION. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products - General considerations USA. 2003. Disponível em: . Acesso em: 20 set 2016.

WANNMACHER, L. Inibidores da bomba de prótons: indicações racionais. Uso Racional de Medicamentos Temas Selecionados, Brasília, v. 2, n. 1, p. 1-6, 2014.

WILLIANMS, C.; MCCOLL, K.E.L. Proton pump inhibitors and bacterial overgrowth. Alim Pharm & Therap., v. 23, p. 3-10, 2012.

YU, M.; LEE, C.; WANG, M.; et al. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci., v. 106, n. 10, p. 1438-47, 2015.


Apontamentos

  • Não há apontamentos.


Direitos autorais 2018 Cadernos UniFOA



Cadernos UniFOA

Campus Três Poços - Av. Paulo Erlei A. Abrantes, 1325 - Três Poços
Prédio 3 - Sala 2 (Casarão)
Volta Redonda - RJ - CEP: 27240-560
Tel.: (24) 3340-8400 – Ramal: 8350

Indexado em:





  • Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.